Print E-mail
Volume 45, Number 1, February 2012

Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections


Chung-Chih Lai, Wang-Huei Sheng, Jann-Tay Wang, Chun-Hsin Liao, Mao-Wang Ho, Chwen-Je Chen, Der-Li Chen, Ming-Uen Chou, Chien-Ming Lee, Yee-Chun Lin, Ming-Ye Pong, Shan-Chwen Chang


Received: May 19, 2010    Revised: September 9, 2010    Accepted: October 20, 2010   

 

Corresponding author:

Shan-Chwen Chang, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Corresponding author. Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.



 

Background and purpose: 

The safety and efficacy of treating serious infections caused by Staphylococcus aureus with daptomycin in a Taiwanese population were studied.

 



 

Methods:

A retrospective, multicenter study was performed in Taiwan between December 2007 and June 2009. This study included adult hospitalized patients who had received intravenous daptomycin therapy for infections caused by S aureus. All patients were followed until discharge from the hospital or death.

 



 

Results:

A total of 52 patients (males, n=44; median age: 62 years) were evaluated. Infections included complicated skin and soft-tissue infections (n=14), catheter-related bacteremia (n=14), osteomyelitis and septic arthritis (n=12), endovascular infections and endocarditis (n=11), and urinary tract infections (n=1). Overall, 47 (90.4%) patients were successfully treated and their clinical symptoms were resolved. Adverse effects related to daptomycin were detected in nine patients, but none were required to discontinue daptomycin.



 

Conclusion:

The results support daptomycin as an effective and safe treatment for staphylococcal infections in Taiwanese populations.



 

Key words:

Daptomycin, Methicillin-resistant Staphylococcus aureus, Serious infection